Vir Biotechnology Inc [VIR] stock is trading at $11.53, up 11.94%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VIR shares have gain 11.83% over the last week, with a monthly amount glided 19.73%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 23, February 2024, Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences. In a post published today on Yahoo Finance, Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of March:.
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on January 29, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $9 from $23. Previously, BofA Securities downgraded its rating to Neutral on September 08, 2023, and dropped its price target to $14. On March 06, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $34 on the stock. Goldman upgraded its rating to a Buy and increased its price target to $53 on February 21, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $30 on January 27, 2023. SVB Leerink started tracking with a Outperform rating for this stock on September 14, 2022, and assigned it a price target of $40. In a note dated September 09, 2022, Morgan Stanley initiated an Underweight rating and provided a target price of $15 on this stock.
Vir Biotechnology Inc [VIR] stock has fluctuated between $7.72 and $27.48 over the past year. Currently, Wall Street analysts expect the stock to reach $31.69 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $11.53 at the most recent close of the market. An investor can expect a potential return of 174.85% based on the average VIR price forecast.
Analyzing the VIR fundamentals
Vir Biotechnology Inc [NASDAQ:VIR] reported sales of 86.18M for the trailing twelve months, which represents a drop of -66.03%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.65 points at the first support level, and at 9.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.12, and for the 2nd resistance point, it is at 12.70.
Vir Biotechnology Inc [VIR] reported earnings per share of -$0.86 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.01/share, meaning a difference of $0.15 and a surprise factor of 14.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.22 per share as compared to estimates of -$1.21 per share, a difference of -$0.01 representing a surprise of -0.80%.
Ratios To Look Out For
For context, Vir Biotechnology Inc’s Current Ratio is 9.05. In addition, the Quick Ratio stands at 10.72 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 18.00, the price to book ratio is 0.98.
Transactions by insiders
Recent insider trading involved SCANGOS GEORGE A, Director, that happened on Feb 20 when 16872.0 shares were sold. Director, SCANGOS GEORGE A completed a deal on Feb 16 to sell 10878.0 shares. Meanwhile, EVP & Chief Medical Officer Pang Phillip sold 3321.0 shares on Feb 16.
